Biopharmaceutical company Biocon Ltd reported a more than six-fold rise in first-quarter profit on Thursday, boosted by a one-time gain from the sale of its Indian branded formulations business.
Biocon said in March it would sell the branded formulations business to Eris Lifesciences in a deal worth 12.42 billion rupees.
"Transaction has come into effect on April 1,2024... Gain of 10.57 billion rupees is accounted after taking into account working capital and expenses incurred towards commercial collaboration," Biocon said.
The company, which counts the United States and Europe as key markets, posted a net profit attributable to shareholders of 6.6 billion rupees ($78.62 million) for the quarter ended June 30, compared with 1.01 billion rupees a year earlier.
The company's quarterly profit was also boosted by the increased market share of its biosimilars, which include treatments for cancer, diabetes and immunology-related conditions. Revenue from its biosimilars segment rose 3.4% to 20.83 billion rupees from a year ago.
However, revenue from its generics segment fell 5.9% to 6.6 billion rupees, hurt by pricing pressure in the U.S. market.
The company's shares closed 2.2% lower on Thursday, ahead of the results.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
